🎉 M&A multiples are live!
Check it out!

TTY Biopharm Valuation Multiples

Discover revenue and EBITDA valuation multiples for TTY Biopharm and similar public comparables like Pharming, Julphar, and Galapagos.

TTY Biopharm Overview

About TTY Biopharm

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.


Founded

1960

HQ

Taiwan
Employees

553

Website

tty.com.tw

Financials

LTM Revenue $180M

LTM EBITDA n/a

EV

$486M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

TTY Biopharm Financials

TTY Biopharm has a last 12-month revenue of $180M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, TTY Biopharm achieved revenue of $178M and an EBITDA of $64.2M.

TTY Biopharm expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See TTY Biopharm valuation multiples based on analyst estimates

TTY Biopharm P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $166M $178M XXX XXX XXX
Gross Profit $91.2M $99.3M XXX XXX XXX
Gross Margin 55% 56% XXX XXX XXX
EBITDA $50.0M $64.2M XXX XXX XXX
EBITDA Margin 30% 36% XXX XXX XXX
Net Profit $33.0M $34.1M XXX XXX XXX
Net Margin 20% 19% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

TTY Biopharm Stock Performance

As of April 15, 2025, TTY Biopharm's stock price is TWD 70 (or $2).

TTY Biopharm has current market cap of TWD 17.4B (or $526M), and EV of TWD 16.1B (or $486M).

See TTY Biopharm trading valuation data

TTY Biopharm Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$486M $526M XXX XXX XXX XXX $0.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

TTY Biopharm Valuation Multiples

As of April 15, 2025, TTY Biopharm has market cap of $526M and EV of $486M.

TTY Biopharm's trades at 2.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate TTY Biopharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for TTY Biopharm and 10K+ public comps

TTY Biopharm Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $486M XXX XXX XXX
EV/Revenue 2.7x XXX XXX XXX
EV/EBITDA 7.6x XXX XXX XXX
P/E 12.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 13.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TTY Biopharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

TTY Biopharm Valuation Multiples

TTY Biopharm's NTM/LTM revenue growth is 3%

TTY Biopharm's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, TTY Biopharm's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate TTY Biopharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for TTY Biopharm and other 10K+ public comps

TTY Biopharm Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 7% XXX XXX XXX XXX
EBITDA Margin 36% XXX XXX XXX XXX
EBITDA Growth 28% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 39% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 22% XXX XXX XXX XXX
G&A Expenses to Revenue 8% XXX XXX XXX XXX
R&D Expenses to Revenue 5% XXX XXX XXX XXX
Opex to Revenue 34% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

TTY Biopharm Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Contract Research & Manufacturing comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

TTY Biopharm M&A and Investment Activity

TTY Biopharm acquired  XXX companies to date.

Last acquisition by TTY Biopharm was  XXXXXXXX, XXXXX XXXXX XXXXXX . TTY Biopharm acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by TTY Biopharm

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About TTY Biopharm

When was TTY Biopharm founded? TTY Biopharm was founded in 1960.
Where is TTY Biopharm headquartered? TTY Biopharm is headquartered in Taiwan.
How many employees does TTY Biopharm have? As of today, TTY Biopharm has 553 employees.
Is TTY Biopharm publicy listed? Yes, TTY Biopharm is a public company listed on ROCO.
What is the stock symbol of TTY Biopharm? TTY Biopharm trades under 4105 ticker.
When did TTY Biopharm go public? TTY Biopharm went public in 2001.
Who are competitors of TTY Biopharm? Similar companies to TTY Biopharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of TTY Biopharm? TTY Biopharm's current market cap is $526M
What is the current revenue of TTY Biopharm? TTY Biopharm's last 12-month revenue is $180M.
What is the current EV/Revenue multiple of TTY Biopharm? Current revenue multiple of TTY Biopharm is 2.7x.
What is the current revenue growth of TTY Biopharm? TTY Biopharm revenue growth between 2023 and 2024 was 7%.
Is TTY Biopharm profitable? Yes, TTY Biopharm is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.